Karen Klein
Pediatric Endocrinology · San Diego, CANPI 1760553515
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by AbbVie at 54.7% of the total. Reporting peaked in 2021 at $46,598 and has fallen 55.2% since, to $20,867 in 2025. Among pediatric endocrinology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $700.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$107K
- Tolmar Pharmaceuticals, Inc.$30K
- Tolmar, Inc.$30K
- Ipsen Innovation$12K
- Arbor Pharmaceuticals, Inc.$8K
- Ipsen Biopharm Limited$3K
- plus $5K from 20 others
Across 137 payments — averaging $4771.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$365K
- Ascendis Pharma Endocrinology Inc$207K
- Eli Lilly$55K
- Tolmar, Inc.$26K
What the payments were for
- Consulting fees$70,42736%
- Speaking & faculty fees$114,20358%
- Travel & lodging$3,9372%
- Food & beverage$5,8423%
- Education$70%
- Charitable contribution$9250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 103 | $106,896 |
| Tolmar Pharmaceuticals, Inc. | 24 | $30,440 |
| Tolmar, Inc. | 20 | $30,032 |
| Ipsen Innovation | 2 | $12,198 |
| Arbor Pharmaceuticals, Inc. | 18 | $7,794 |
| Ipsen Biopharm Limited | 1 | $2,960 |
| Ironwood Pharmaceuticals, Inc | 2 | $2,260 |
| Novo Nordisk | 30 | $669 |
| Ferring Pharmaceuticals Inc. | 12 | $306 |
| Dexcom, Inc. | 9 | $255 |
| BETA Bionics, Inc. | 10 | $248 |
| Ipsen Biopharmaceuticals, Inc | 8 | $240 |
| Azurity Pharmaceuticals, Inc. | 10 | $227 |
| Eton Pharmaceuticals, Inc. | 2 | $123 |
| Ascendis Pharma Endocrinology Inc | 4 | $115 |
| Pfizer | 5 | $93 |
| Neurocrine Biosciences, Inc. | 3 | $89 |
| Kyowa Kirin, Inc. | 3 | $76 |
| Insulet Corporation | 2 | $61 |
| Medtronic | 2 | $56 |
| Tandem Diabetes Care, Inc. | 2 | $49 |
| Sandoz | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| AstraZeneca | 1 | $24 |
| Amgen | 1 | $23 |
| Lilly USA, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lupron Depot$98,931
- FENSOLVI$53,920
- Triptodur$7,532
- ELIGARD$6,116
- LINZESS$2,250
How this compares
$195,341 in reported general payments places this provider in the 95th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in San Diego
- Marcela Vargas TrujilloSan Diego$57K
- Ron NewfieldSan Diego$27K
- Michael GottschalkSan Diego$17K
- Susan PhillipsSan Diego$12K
- Maja MarinkovicSan Diego$5K
- Mary PattersonSan Diego$4K
- Jane KimSan Diego$3K
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
- Francine KaufmanLos Angeles$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.